Abstract
Science is a branch of scholarship: it provides explanations for material phenomena in terms of matter and energy. Medicine by contrast is a trade: it applies scientific knowledge but also requires nonscientific skills such as empathy. Neurochemistry is the science that deals with the molecules that make up nervous systems and with their interactions. Neurology and psychiatry are the trades of those who try to help people with diseases of the nervous system to heal. Scientists including neurochemists have the luxury of taking the time needed to probe deeply into the phenomena they study. Neurologists and psychiatrists more often face sharp constraints on how long they can take to try to help the sick human beings for whom they care. Examples used to illustrate this distinction include psychoses and demyelinating diseases. The existence of a large and often impressive body of scholarship in neurology and psychiatry can foster the illusion that these are scholarly rather than fundamentally practical activities. For convenience, modern physicians conceptualize the phenomena they see as discrete “diseases.” Sometimes their concepts turn out to be scientifically valid. Often, sadly, they do not. The current chapter deals with neurochemical mechanisms rather than listing abnormalities in molecules in clinically defined “diseases.” Neurochemical mechanisms in sick people are real-world entities that can be discovered by observation and whenever possible by experimentation. “Diseases” are abstractions constructed by physicians and others to help figure out what is wrong with patients and how to try to help. This chapter is on the chemistry of nervous systems of people whose actions are unusual enough to draw medical attention to them. It does not deal with such nonmaterial concepts as “free will” or “the soul,” nor with the relationship of mind to brain. This limitation is intentional and potentially powerful. A neurologist or psychiatrist armed with the array of chemicals that constitute the modern pharmacopeia can do much more than even the most sympathetic and understanding physician or other counselor who is limited to “talk therapy.” Sigmund Freud and his fellow alienists in Vienna at the turn of the last century yearned to have such medicines available. In general, the Viennese-trained psychiatrists who fled to the United States were perfectly willing to use psychotropic medications, although they made sure to talk extensively to their patients as well. Even the psychoanalysts in that group held to the slogan, “There is also a brain.” Despite the disputes among “schools of psychoanalysis” that went on with talmudic intensity, the able among those practitioners never forgot that their goal was to aid the troubled individuals who came to them for help.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alvarez LM, Castillo ST, Perez ZJA, Vargas RI, Sepulveda GR, Zuniga CMA (1995) Activity of aryl sulfatase a enzyme in patients with schizophrenic disorders. Rev Invest Clin 47:387–392
Argov Z&Navon R (1984) Ann Neurol 16:14–20
Candler PM, Dale RC, Griffin S, Church AJ, Wait R, Chapman MD, Keir G, Giovannoni G, Rees JH (2006 Apr) Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry 77(4):507–512
Caspi A, Moffit TE, Cannon M, McClay J, Murray R, Harrington H et al (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X-environment interaction. Biol Psychiatry 57:1117–1127
Craddock N, O’Donovan MC, Owen MJ (2006) Genes for schizopohrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 32:9–16
Drory VE et al (2003) Muscle Nerve 28:109–112
Duenas AM, Gold R, Giunti P (2006) Molecular pathogenesis of spinocerebellar ataxias. Brain 129(Pt 6):1357–1370, Epub 2006 Apr 13
Galbraith DA, Gordon BA, Feleki V, Gordon N, Cooper AJ (1989) Metachromatic leukodystrophy (MLD) in hospitalized adult schizophrenic patients resistant to drug treatment. Can J Psychiatry 34:299–302
Goodman AB (1994) Medical conditions in Ashkenazi schizophrenic pedigrees. Activity of aryl sulfatase a enzyme in patients with schizophrenic disorders. Schizophr Bull 20:507–517
Gravel RA et al (1995) In: Scriver CR et al (eds) Metabolic and molecular basis of inherited disease, 7th edn. McGraw-Hill, New York, NY, pp 2839–2882
Green EK, Raybould R, MacGregor S, Gordon-Smith K, Heron J, Hyde S et al (2005) Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic bounderies to increase risk for bipolar disorder. Arch Gen Psychiat 62:642–648
Hammer MB (1998) Psychosomatics 39:446–448
Hendriksz CJ et al (2004) J Inherit Metab Dis 27:241–249
Herska M, Moscovich DG, Kalian M, Gottlieb D, Bach G (1987 Mar) Aryl sulfatase a deficiency in psychiatric and neurologic patients. Am J Med Genet 26(3):629–635
Iype M et al (2006) Ann Ind Acad Neurol 9:110–112
Kendell RE (1975) The role of diagnosis in psychiatry. Blackwell, London, See also: Kendell RE (2002) The distinction between personality disorder and mental illness. Br J Psychiat 180:110–115
Leonard S, Freedman R (2006) Genetics of chromosome 15q13-q14 in schizophrenia. Biol Psychiatry 60:115–122
Lichtenberg P et al (1988) Br J Psychiat 153:387–389
Lodi R, Tonon C, Calabrese V, Schapira AH (2006) Friedreich’s ataxia: from disease mechanisms to therapeutic interventions. Antioxid Redox Signal 8:438–443
Meek D et al (1984) Ann Neurol 15:348–352
Navon R et al (1973) Am J Human Genet 25:287–292
O’Neill B et al (1978) Neurology 28:1117–1123
Oonk JGW et al (1979) Neurology 29:380–384
Porteus DJ, Thompson P, Brandon NJ, Millar JK (2006) The genetics and biology of DISC 1 – an emerging role in psychosis and cognition. Biol Psychiatry 60:123–131
Posner JB (2003 Sept) Immunology of paraneoplastic syndromes: overview. Ann N Y Acad Sci 998:178–186
Rapin I et al (1976) Arch Neurol 33:120–130
Renshaw PF et al (1992) Ann Neurol 31:342–344
Rosebush PI et al (1995) J Clin Psychiat 56:347–353
Skolnick EM (2006) Mechanisms of action of medicines for schizophrenia and bipolar illness: status and limitations. Biol Psychiatry 59:1039–1045
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Blass, J.P. (2011). Mechanisms Versus Diagnoses. In: Blass, J. (eds) Neurochemical Mechanisms in Disease. Advances in Neurobiology, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7104-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7104-3_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7103-6
Online ISBN: 978-1-4419-7104-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)